AVITA Medical restructures PermeaDerm deal, securing a higher revenue share, a $500K expansion option, and a $1M minimum for 2026
RCEL has more than doubled off its 52-week low of $3.22 on elevated volume (1.9× avg).
Summary
AVITA Medical amended its PermeaDerm agreements with Stedical Scientific, increasing its revenue share to 67–80%, paying $500K for an option to expand into Europe/UK/Australia, and committing to $1M in minimum revenue-sharing payments in 2026, growing 20% annually through 2030.
Key Events · M&A and Partnerships · RCEL
-
Global Amendment Signed
On August 5, 2026, AVITA Medical and Stedical Scientific entered a Global Amendment to their existing distribution and manufacturing agreements for PermeaDerm, effective immediately.
-
Revenue Share Increased
The revenue share for PermeaDerm rises to 67% for sheet-form products, with additional gross margin participation above 50%, and to 80% for glove-form products, with additional participation above 35% gross margin.
-
$500K Expansion Option
A $500,000 fee secures the right of first offer and refusal to expand the exclusive distribution territory into the European Union, United Kingdom, and/or Australia, payable by January 15, 2027.
-
2026 Minimum Revenue Sharing of $1M
The amendment sets a $1.0 million minimum revenue-sharing payment for 2026, with 20% annual growth minimums through 2030, and waives all prior minimum payment requirements.
Analysis · RCEL · Industrial Applications And Services
AVITA Medical has restructured its PermeaDerm distribution and manufacturing agreements with Stedical Scientific, locking in a larger slice of product revenue—67% on sheet-form and 80% on glove-form sales—alongside a $500,000 option to expand into Europe, the UK, or Australia. The deal also establishes a $1.0 million minimum revenue-sharing payment for 2026, escalating 20% annually through 2030, and permits Stedical to enter certain U.S. markets that AVITA does not currently serve. By securing more favorable economics for its core wound-care product and opening a path to international markets, the amendment directly addresses the going-concern risk through a strengthened key revenue stream.
At the time of this filing, RCEL was trading at $8.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $253.6M. The 52-week trading range was $3.22 to $8.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.